Steal this grant

Staphylococcus aureus

Overall 4/9. Strong, fundable premise: dissects WHY adjunctive phage works rather than re-running the diSArm efficacy trial

Acinetobacter baumannii

Overall 2/9. Outstanding topic-funder fit: a WHO/CDC priority pathogen whose first modern Western phage cure was itself A. baumannii, mapped directly onto NIAID's AMR mission.

Klebsiella pneumoniae

Overall 4/9. Compelling, mission-aligned hook: phage escape disarms CRKP (virulence loss; resensitization in one CRKP system), directly on NIAID AMR priorities

Pseudomonas aeruginosa

Overall 3/9. Direct, indication-specific mechanistic anchor (Weissfuss 2025 ventilated-mouse model) used correctly to justify antibiotic-sparing adjunctive phage

Enterococcus faecium

Overall 2/9. Fundable core mechanism: phages as a daptomycin resensitizer via collateral sensitivity, anchored to real ex vivo (Kunz Coyne 2023) and human-case (Stellfox 2024) evidence.

Enterobacter cloacae complex

Overall 3/9. Tightly scoped, fundable R21 that transports four recent single-center non-U.S. ECC phage findings into a real U.S.-specific gap (strain-specific host range untested domestically)

Stenotrophomonas maltophilia

Escherichia coli (ESBL)

Overall 3/9. Correctly characterized, verified evidence anchors: the Gainey 2023 case report (17 y/o renal-transplant recipient, 4 ESBL urosepsis episodes in 4 months, ertapenem and fecal transplant failed, 2-phage IV cocktail, 4-year culture-negative cure) and ELIMINATE Part 1 (randomized open-label, combined intraurethral+IV LBP-EC01 with oral TMP-SMX, well tolerated, rapid E. coli reduction).

Pseudomonas aeruginosa

Overall 3/9. Operationalizes the in-vivo-validated evolutionary trade-off (Chan 2025) as a prospectively testable selection rule, not reactive host-range matching

Mycobacterium abscessus

Overall 3/9. Exceptionally strong, well-cited clinical precedent (first-in-human engineered phage therapy; 20-patient compassionate-use series) gives a compelling, credible hook for a novel modality.

Burkholderia cepacia complex

Overall 4/9. Targets the real bottleneck — scarce lytic Burkholderia phages and the lack of a matching pipeline — not whether phages can kill Bcc.

Pseudomonas aeruginosa

Overall 3/9. Strong launchpad: a completed Phase 2 RCT (Tailwind) plus a single inhalable target pathogen, with a clearly defined mechanistic gap.

Mycobacterium avium

Overall 3/9. Honest, well-calibrated evidence framing: one anchor human case (Muddy IV) plus preclinical discovery treated as proof-of-concept, not adoption-ready

S. aureus / S. pneumoniae

Overall 3/9. Strong, mission-aligned hook: post-viral secondary MRSA pneumonia as a pandemic-mortality driver with a credible human anchor (AP-SA02)

S. aureus / coag-neg staph

Overall 3/9. Quantified preclinical anchor (~22.5-fold phage+vancomycin synergy) plus two human salvage cases give a credible, evidence-grounded rationale.

S. aureus

Overall 3/9. Mechanistically airtight thesis: failure framed as antibiotic tolerance/sequestration, not resistance, with each phage property mapped to a specific reservoir (biofilm, intracellular, SCV).

S. aureus

Overall 3/9. Mechanistically coherent bench-to-trial design tightly aligned with NIDDK's diabetes-complications mission

Polymicrobial

Overall 3/9. Phages framed as a biofilm-targeting adjunct to DAIR (never a standalone cure), tightly grounded in the four allowed references

Staphylococci

Overall 3/9. Built around resolving a real published contradiction (Pitton positive vs. Molendijk negative/antagonistic), making strain/dose/sequence/timing the primary variable instead of assuming efficacy

S. aureus / Enterococcus

Overall 3/9. Mechanistically compelling, tightly NHLBI-aligned premise (valve biofilm/persisters/relapse) with phage framed as an orthogonal adjunct, not a replacement

S. aureus / P. aeruginosa

Overall 3/9. Coherent mechanism-to-IND arc across three logically sequenced aims (host range/biofilm to in-vivo PD/resistance to phagogram/CMC).

P. aeruginosa / A. baumannii

Overall 4/9. Strong, well-grounded hook: PhagoBurn's under-dosing reframed as a fixable problem, cited only to allowed references with no citation drift

Polymicrobial biofilm

Overall 4/9. Compelling, NINR-aligned premise: polymicrobial biofilm reframed as the explicit therapeutic target with phage mechanisms mapped onto it

S. aureus

Overall 3/9. Honest, indication-matched evidence base (DUOFAG, AP-SA02, Rubalskii, 2025 review) that builds on the exact standardization gap those sources name without overstating efficacy

Cutibacterium acnes

Overall 4/9. Strong, well-aligned premise: strain-selective phage editing of C. acnes dysbiosis maps directly onto NIAMS dermatology and AMR-stewardship priorities

Escherichia coli

Overall 4/9. Mechanism-driven rationale linking phage biology to the specific antibiotic failure modes of rUTI (intracellular reservoirs, biofilms, microbiome collapse).

E. coli / Proteus / Enterococcus

Overall 3/9. Strong dual-mode concept (phage-armed catheter for prevention + intravesical cocktail for treatment) targeting the right E. coli/Proteus device niche where antibiotics fail

E. coli / Enterococcus

Overall 3/9. Mechanism-to-failure-mode logic is tight and every allowed citation is used accurately and only where it fits

Proteus mirabilis

Overall 4/9. Original, mechanism-anchored hook: phage judged by suppression of urease activity and urine-pH rise (the proximal cause of struvite crystallization), not bacterial killing alone

Klebsiella / CRE

Overall 3/9. Reproducible preclinical premise with a concrete PD target (>=3x10^8 PFU/g stool) and a mechanistic capsule-as-trap rationale from two independent murine studies

Klebsiella pneumoniae

Overall 3/9. Strong subtractive-microbiome concept: removing a defined causal Kp pathobiont instead of broadly suppressing host immunity — a clear, fundable inversion of standard IBD therapy.

AIEC (LF82-type)

Overall 3/9. Targets a real, fundable gap: durable suppression of the mucosa-adherent (not just fecal) AIEC reservoir, which the cited literature leaves open

Clostridioides difficile

Overall 4/9. Mission-aligned framing: targets the antibiotic-driven microbiome-collapse cycle and positions phage as a microbiome-sparing adjunct to approved restoration therapies

Helicobacter pylori

Overall 3/9. Honest, field-accurate premise: mines the rare intact-prophage reservoir and pivots to engineered endolysins rather than chasing scarce lytic phages

Gut E. coli / Enterococcus

Overall 3/9. Every mechanistic claim is grounded in one of the four allowed references with no overstatement (each citation verified against source).

Cytolytic Enterococcus faecalis

Overall 3/9. Causally validated, biomarker-paired target (cytolysin-positive E. faecalis tied to mortality; Duan 2019) — not a generic dysbiosis pitch

Klebsiella pneumoniae

Overall 2/9. Exceptionally clean target: a single causal, culturable pathobiont (Kp) with a defined gut-liver Th17 mechanism, backed by mouse efficacy and human oral-phage safety data

Enterococcus / Enterobacteriaceae

Overall 3/9. Tight mechanistic chain: explanted-stent colonization data (Schneider 2014) pinpoint the exact target organisms, and each pathogen arm has direct hepatobiliary phage precedent (Ichikawa 2023; Duan 2019; Paul 2021).

Urease-producing gut flora

Overall 3/9. Tight single-node mechanism (deplete urease-bearing bacteria) cleanly differentiated from lactulose/rifaximin

Fusobacterium nucleatum (Fna C2)

Overall 3/9. Mechanistically grounded and tightly cited: every claim maps to one of the four allowed papers, which form a convergent delivery + immune-remodeling + lytic-phage + biomarker evidence base

Deleterious response-blunting taxa

Overall 3/9. Compelling subtractive-tool hook: phages do what antibiotics/FMT cannot — remove one harmful taxon while sparing ICI-required commensals

S. aureus biofilm

Overall 4/9. Strong translational logic chain (ex vivo biofilm to sheep model to Phase 1 safety to randomized efficacy trial), with each step mapped to one of the four allowed references.

Porphyromonas gingivalis

Overall 3/9. Strategically sound endolysin-first pivot that is faithful to the only 2025 efficacy signal and to the documented whole-phage isolation barrier

Streptococcus mutans

Overall 3/9. Clean, compelling premise — one dominant pathogen plus a microbiome-sparing modality is an ideal phage-therapy target, and the cocktail-vs-resistance hook is mechanistically grounded in the cited M102/φAPCM01 work.

P. aeruginosa

Overall 4/9. Strong, citation-grounded mechanistic rationale; the three preclinical refs genuinely converge on topical anti-pseudomonal phage efficacy and biofilm tropism

P. aeruginosa / S. aureus

Overall 3/9. Compelling, NIDCD-aligned rationale: an accessible, localized, biofilm-driven middle-ear infection is a strong phage-therapy target, with a coherent three-aim de-risking arc fit for an R21.

Gardnerella vaginalis

Overall 3/9. Mechanistically matched to the two precise failure points of antibiotics (biofilm penetration and lactobacillus collateral damage), with the biofilm reframed as the drug's own substrate.

MDRO reservoirs

Overall 3/9. Tightly scoped transmission-science premise that aligns cleanly with NIAID AMR/HAI priorities and uses all four allowed references accurately and without redundancy

Listeria / Salmonella / E. coli O157

Overall 3/9. Strong USDA-SBIR fit: clean-label, residue-free, GRAS-track biocontrol with a credible Phase I to II commercialization arc and concrete product formats

Salmonella / Vibrio / Aeromonas

Overall 3/9. Defensible, fully reference-grounded science: every phage-biology and efficacy claim maps to one of the four allowed references, and the cross-commodity Salmonella/Vibrio/Aeromonas platform is a real innovation rather than a single-product study.